Uveal Melanoma Immunogenomic Score Shows Predictive Potential
Source: OncLive, May 2024
Investigators examined 100 metastases and developed a Uveal Melanoma Immunogenomic Score to predict which patients will respond to immunotherapy.
Investigators have developed a Uveal Melanoma Immunogenomic Score (UMIS) to predict which patients with metastatic uveal melanoma will respond to immunotherapy, according to findings published in Nature Communications.
“The dogma was that uveal melanoma is a ‘cold’ cancer, meaning that T cells can’t get into these tumors,” senior author Udai Kammula, MD, FACS, an associate professor of surgery at the University of Pittsburgh and director of the Solid Tumor Cell Therapy Program at UPMC Hillman Cancer Center, in Pennsylvania, said in a press release.2 “We show that T cells are in fact infiltrating metastases and they’re getting activated, but they’re just sitting there in a dormant state because something in the tumor is suppressing them. Adoptive therapy allows us to rescue these cells from the suppressive tumor microenvironment and successfully treat some patients.”